Objective To investigate the diagnostic value of serum calcium and phosphorus levels in the progression of bone metastasis of breast cancer during zoledronic acid therapy.
Methods The clinical features were collected from breast cancer patients who underwent zoledronic acid therapy and had bone metastasis in Zhongshan Hospital, Fudan University between January 2014 and December 2019. A single sample t-test was performed to analyze the changes in serum calcium and phosphorus levels over time.
Results Forty-two female patients with bone metastasis breast cancer were included, with a mean age of (53.67 ±11.07) years. During zoledronic acid treatment, the serum calcium and phosphorus levels 1 month, 2 months, 3 months and 6 months before progression of bone metastasis were not statistically different from those at the baseline (P>0.05).
Conclusions For breast cancer patients with bone metastasis progression, changes in serum calcium and phosphorus levels may not reflect the progression of bone metastases earlier than imaging examination.
DownLoad: